Prenetics Global (NASDAQ:PRE) Trading Down 0.2% – Here’s Why

Prenetics Global Limited (NASDAQ:PRE)’s stock price fell 0.2% on Thursday . The company traded as low as $20.20 and last traded at $20.79. 378,111 shares were traded during mid-day trading, an increase of 36% from the average session volume of 277,085 shares. The stock had previously closed at $20.83.

Analyst Ratings Changes

A number of research firms have recently weighed in on PRE. Roth Mkm began coverage on shares of Prenetics Global in a research report on Wednesday, February 11th. They issued a “buy” rating and a $36.00 target price on the stock. Wall Street Zen cut shares of Prenetics Global from a “buy” rating to a “hold” rating in a research note on Monday, February 16th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Prenetics Global in a research note on Tuesday, April 21st. Finally, Lake Street Capital began coverage on shares of Prenetics Global in a research note on Monday, March 16th. They issued a “buy” rating and a $29.00 price target on the stock. Three equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $32.33.

Prenetics Global Trading Down 4.5%

The company has a market cap of $335.12 million, a P/E ratio of -4.94 and a beta of 0.24. The stock’s 50 day moving average is $18.20 and its 200-day moving average is $17.57.

Prenetics Global declared that its board has initiated a stock buyback plan on Friday, March 6th that authorizes the company to buyback $40.00 million in outstanding shares. This buyback authorization authorizes the company to reacquire up to 15.8% of its stock through open market purchases. Stock buyback plans are often a sign that the company’s board believes its shares are undervalued.

Hedge Funds Weigh In On Prenetics Global

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Jane Street Group LLC bought a new position in Prenetics Global during the 4th quarter valued at about $1,302,000. 683 Capital Management LLC bought a new position in Prenetics Global during the 4th quarter valued at about $1,181,000. Aberdeen Group plc bought a new position in Prenetics Global during the 3rd quarter valued at about $979,000. Millennium Management LLC bought a new position in Prenetics Global during the 4th quarter valued at about $810,000. Finally, Marshall Wace LLP bought a new position in Prenetics Global during the 4th quarter valued at about $788,000. Institutional investors own 25.01% of the company’s stock.

Prenetics Global Company Profile

Prenetics Global (NASDAQ: PRE) is a molecular diagnostics and genetic testing company that delivers a broad range of laboratory and at-home testing solutions. The company’s core offerings include next-generation sequencing (NGS) panels for hereditary health risks, pharmacogenomic reports to guide medication choices, and comprehensive consumer DNA testing services. In addition to genetic insights, Prenetics provides infectious disease diagnostics—most notably real-time PCR testing for pathogens such as SARS-CoV-2—through an integrated platform that combines sample collection, laboratory processing and digital reporting.

Serving both business-to-consumer and business-to-business markets, Prenetics operates a network of laboratories and service centers across Asia Pacific, Europe, the Middle East and North America.